Dimensional Fund Advisors LP boosted its position in shares of Luminex Corporation (NASDAQ:LMNX) by 2.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,718,886 shares of the medical instruments supplier’s stock after buying an additional 33,650 shares during the period. Dimensional Fund Advisors LP owned 4.20% of Luminex Corporation worth $31,576,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans boosted its position in shares of Luminex Corporation by 5.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 21,400 shares of the medical instruments supplier’s stock worth $433,000 after buying an additional 1,090 shares during the last quarter. Creative Planning boosted its position in shares of Luminex Corporation by 5.4% in the first quarter. Creative Planning now owns 9,256 shares of the medical instruments supplier’s stock worth $170,000 after buying an additional 474 shares during the last quarter. Karp Capital Management Corp bought a new position in shares of Luminex Corporation during the first quarter worth about $225,000. State Street Corp boosted its position in shares of Luminex Corporation by 7.7% in the fourth quarter. State Street Corp now owns 893,438 shares of the medical instruments supplier’s stock worth $18,072,000 after buying an additional 63,926 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its position in shares of Luminex Corporation by 58.8% in the first quarter. Nationwide Fund Advisors now owns 48,593 shares of the medical instruments supplier’s stock worth $893,000 after buying an additional 17,996 shares during the last quarter. Institutional investors own 73.36% of the company’s stock.
Shares of Luminex Corporation (NASDAQ LMNX) opened at 18.95 on Friday. The company has a market capitalization of $835.15 million, a PE ratio of 58.67 and a beta of 0.29. The firm’s 50-day moving average price is $20.30 and its 200 day moving average price is $19.62. Luminex Corporation has a 52 week low of $17.64 and a 52 week high of $23.62.
Luminex Corporation (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.11. The company had revenue of $76.50 million for the quarter, compared to the consensus estimate of $75.45 million. Luminex Corporation had a net margin of 4.72% and a return on equity of 4.81%. Luminex Corporation’s revenue was up 19.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.33 earnings per share. Equities analysts predict that Luminex Corporation will post $0.54 EPS for the current year.
WARNING: “Dimensional Fund Advisors LP Acquires 33,650 Shares of Luminex Corporation (LMNX)” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/08/19/dimensional-fund-advisors-lp-raises-stake-in-luminex-corporation-lmnx-updated-updated.html.
Several brokerages recently commented on LMNX. BidaskClub lowered Luminex Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. TheStreet lowered Luminex Corporation from a “b” rating to a “c+” rating in a report on Monday, August 7th. Zacks Investment Research raised Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a report on Monday, July 17th. ValuEngine lowered Luminex Corporation from a “hold” rating to a “sell” rating in a report on Saturday, July 8th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $21.00 price objective on shares of Luminex Corporation in a research report on Friday, June 9th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. Luminex Corporation currently has a consensus rating of “Hold” and an average target price of $21.60.
In other news, Director G Walter Loewenbaum II sold 25,000 shares of the firm’s stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $20.07, for a total value of $501,750.00. Following the transaction, the director now owns 713,896 shares of the company’s stock, valued at approximately $14,327,892.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.90% of the company’s stock.
About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
What are top analysts saying about Luminex Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Luminex Corporation and related companies.